Roche gains RA drug for $370M
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Roche |
Toyama Chemical |
$370M licensing deal |
Roche will develop and commercialize T-5224, Toyama Chemical's Phase I rheumatoid arthritis drug. |
|
Merck |
SurModics |
$288M deal |
Merck has gained rights to jointly develop and commercialize SurModics' I-vation drug delivery platform for use with the pharma giant's drugs for diseases of the eye. |
|
Biogen Idec |
Cardiokine |
$200M promotion deal |
Cardiokine's drug is poised to enter late-stage development for hyponatremia, a condition characterized by a lack of sodium in the bloodstream. |
|
Par Pharmaceutical |
Loramyc |
$65M licensing deal |
Par gains the U.S. rights to the antifungal therapy Loramyc from France's BioAlliance Pharma. |
|
The Medicines Company |
Nycomed |
$45M reacquisition deal |
The Medicines Company has agreed to pay $45 million to reacquire the European rights to the anticoagulant Angiox from Nycomed. |
|
FazaClo |
Avanir |
$42M sale |
Avanir has sold its schizophrenia drug FazaClo to Ireland's Azur. The move gives Avanir more money to focus on the development of Zenvia for involuntary emotional expression disorder. |
|
Genzyme |
Ceregene |
$25M deal |
Genzyme has agreed to pay $25 million up front to partner with Ceregene on CERE-120, its experimental lead therapy being developed for Parkinson's. |